In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and ...

Elevara Medicines secured $70 million in Series A funding to advance ELV001's Phase II trial for rheumatoid arthritis and explore other chronic inflammatory conditions. Pharma investments surge as ...

Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...

MJH Life Sciences’ acquisition of BPD Healthcare represents a major expansion of strategic capabilities for MJH across ...

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...

Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...

mRNA-based COVID vaccines significantly improve survival rates in cancer patients undergoing immunotherapy, particularly in ...

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

Innovent Biologics and Takeda announced a strategic global collaboration aiming to advance next-generation IO and ADC cancer ...

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies ...

The solution lies in flexibility. Sites need to be able to work in whatever formats make sense for them, whether that’s a ...